The ACTN4 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ACTN4 gene encoding alpha-actinin-4. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of edited cells that enables robust analysis of ACTN4-dependent phenotypes without clonal artifacts. The polyclonal format reflects the natural variability of gene editing outcomes and is particularly suited for bulk functional studies where pooled population behavior recapitulates average knockout effects, avoiding the selection bias inherent in monoclonal lines. Researchers can use this knockout model to investigate the molecular mechanisms by which ACTN4 regulates actin cytoskeleton organization, cell adhesion dynamics, and invasive potential in a human liver cancer context.
The host cell line SK-HEP-1 is a well-characterized human hepatocellular carcinoma (HCC) line originally derived from the ascitic fluid of a 52-year-old male with liver adenocarcinoma. Notably, SK-HEP-1 cells exhibit a unique dual phenotype expressing both epithelial and endothelial markers, including cytokeratins and von Willebrand factor, which makes them an attractive model for studying tumor cell plasticity and vascular mimicry. This endothelial-like characteristic in a liver cancer background provides a distinctive platform to explore how ACTN4 modulates the interplay between adhesion-mediated signaling and cytoskeletal remodeling during cancer progression and metastasis.
ACTN4 functions as a critical actin crosslinking protein that bridges actin filaments to focal adhesion complexes, directly interacting with vinculin, integrin beta1 (ITGB1), paxillin, and focal adhesion kinase (FAK). This interaction network physically anchors the actin cytoskeleton to the plasma membrane and facilitates mechanotransduction. Upstream, ACTN4 expression is regulated by TGF-beta, epidermal growth factor (EGF), and PI3K/Akt signaling, as well as the transcription factor Sp1 and mechanical stress. Downstream, ACTN4 promotes activation of FAK and Src kinase cascades, leading to Rac1-dependent lamellipodia formation and RhoA/Arp2/3-mediated actin polymerization, which drive cell migration and invasion. Additional interacting partners include PDLIM1 and TRIP6, which further scaffold signaling complexes at adhesion sites.
In the SK-HEP-1 hepatocellular carcinoma context, disruption of ACTN4 significantly impairs actin cytoskeletal integrity and focal adhesion maturation, resulting in attenuated signaling through FAK and PI3K/Akt pathways. This knockout model closely mimics the reduced metastatic potential observed when ACTN4 function is lost in aggressive liver cancer cells. Because SK-HEP-1 cells inherently exhibit migratory and invasive behavior, the ACTN4 knockout population serves as an ideal tool to dissect the specific contribution of alpha-actinin-4 to HCC progression, integrin-mediated adhesion, and the signaling crosstalk that underlies collective cell movement.
This polyclonal knockout product is designed for a broad spectrum of functional assays, including fluorescence microscopy with phalloidin staining to visualize actin stress fibers, immunofluorescence for vinculin and paxillin to assess focal adhesion plaque formation, and quantitative western blotting to confirm ACTN4 depletion and monitor phospho-FAK and phospho-Akt levels. Researchers can employ wound healing and transwell invasion assays to quantify migration and invasiveness, as well as cell adhesion and Rho GTPase activation assays to analyze early signaling events. The model is valuable for anti-metastatic drug screening, mechanistic studies of integrin signaling, and validation of ACTN4 as a therapeutic target in HCC. For further technical information or to discuss customized solutions, please contact Ascent Research.
